The Omicron variant of SARS-CoV-2 is causing a rapid increase in infections across the
globe. This new variant of concern carries an unusually high number of mutations in key …

Background While the leading symptoms during coronavirus disease 2019 (COVID-19) are
acute and the majority of patients fully recover, a significant fraction of patients now …

Human antibodies to human immunodeficiency virus-1 (HIV-1) can neutralize a broad range
of viral isolates in vitro and protect non-human primates against infection 1 , 2 . Previous …

Background Heterologous vaccine regimens have been widely discussed as a way to
mitigate intermittent supply shortages and to improve immunogenicity and safety of COVID-19 …

COVID ‐19 pandemic caused by SARS ‐CoV‐2 infection is a public health emergency. COVID
‐19 typically exhibits respiratory illness. Unexpectedly, emerging clinical reports indicate …

Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …

Monoclonal antibody 10-1074 targets the V3 glycan supersite on the HIV-1 envelope (Env)
protein. It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far. Here …

Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …

The SARS-CoV-2 pandemic has unprecedented implications for public health, social life,
and the world economy. Because approved drugs and vaccines are limited or not available, …

Understanding antibody-based SARS-CoV-2 immunity is critical for overcoming the COVID-19
pandemic and informing vaccination strategies. We evaluated SARS-CoV-2 antibody …